 |
LG CNS' headquarters in southwest Seoul/ Courtesy of LG CNS |
The company will participate in the Ministry of Health and Welfare's R&D project for clinical and preclinical drug development, a four-year, three-month initiative backed by about 37.1 billion won ($25 million) in government funding.
LG CNS will lead the development of an AI-based clinical trial design and support platform, integrating various drug development AI models through agentic AI technology.
The platform will employ federated learning, allowing hospitals and research institutes to jointly train AI models without sharing sensitive medical data externally. Industry sources note that drug development typically takes 10 to 15 years and carries a 90 percent failure rate at the clinical trial stage, with fragmented trial structures and limited data access long cited as structural barriers.
In the private sector, LG CNS has completed an agentic AI-powered system for Chong Kun Dang that automates the creation of Annual Product Quality Review reports. The solution deploys about 30 AI agents that autonomously collect, analyze and verify data from quality management and laboratory information systems, slashing document generation time by more than 90 percent.
"We are delivering tangible results after gaining recognition for our pharma and bio AI transformation capabilities from both the government and pharmaceutical companies," said Kim Tae-hoon, senior vice president of LG CNS' AI & Cloud Business Division.
Kim Dong-young Business Reporter davekim0807@ajupress.com
- Copyright ⓒ [아주경제 ajunews.com] 무단전재 배포금지 -
이 기사의 카테고리는 언론사의 분류를 따릅니다.